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Background: The aim of this multicenter trial was to prospectively evaluate neo-adjuvant chemotherapy followed by
extrapleural pneumonectomy (EPP) and radiotherapy, including quality of life as outcome.
Patients and methods: Eligible patients had malignant pleural mesothelioma of all histological types, World Health
Organization performance status of zero to two and clinical stage T1–T3, N0–2, M0 disease considered completely
resectable. Neo-adjuvant chemotherapy consisted of three cycles of cisplatin and gemcitabine followed by EPP.
Postoperative radiotherapy was considered for all patients.
Results: In all, 58 of 61 patients completed three cycles of neo-adjuvant chemotherapy. Forty-five patients (74%)
underwent EPP and in 37 patients (61%) the resection was complete. Postoperative radiotherapy was initiated in
36 patients. The median survival of all patients was 19.8 months [95% confidence interval (CI) 14.6–24.5]. For the
45 patients undergoing EPP, the median survival was 23 months (95% CI 16.6–32.9). Psychological distress
showed minor variations over time with distress above the cut-off score indicating no morbidity with 82% (N = 36)
at baseline and 76% (N = 26) at 3 months after surgery (P = 0.5).
Conclusions: The observed rate of operability is promising. A median survival of 23 months for patients undergoing
EPP compares favourably with the survival reported from single center studies of upfront surgery. This approach was
not associated with an increase in psychological distress.
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introduction
In Europe, the incidence of malignant pleural mesothelioma
(MPM) is continuing to rise with a peak of the epidemic
expected around the year 2015 [1–3]. In the past, there was
a tendency to associate MPM with a sense of hopelessness and
specific oncologic care was not offered to many patients. This
situation has changed recently with evidence that
chemotherapy palliates symptoms [4, 5] and the demonstration
of a survival benefit with the addition of the folate antagonists
pemetrexed or raltitrexed to cisplatin [6, 7].
The role of surgery for earlier stages of pleural MPM
continues to be a matter of debate [8]. Extrapleural
pneumonectomy (EPP) in combination with adjuvant
chemotherapy is, however, the only procedure which has been
associated with long-term survival and even cure in selected
patients. The largest published experience with this procedure
in conjunction with adjuvant chemotherapy and radiotherapy
has been published by the group at the Brigham’s Hospital
in Boston, MA. An update from this group included 183
patients intended for the trimodality approach [9]. The median
survival in the 176 patients alive after surgery was 19 months
and the estimated 2- and 5-year survival was 38% and 15%,
respectively. The perioperative mortality of EPP was reported
to be up to 31% in an initial series [10]; however, with more
experience and better preoperative management, the mortality
has decreased to between 3.4 and 6.8% [11–13].
o
ri
g
in
a
l
a
rt
ic
le
*Correspondence to: Dr R. A. Stahel, Clinic and Policlinic of Oncology, University
Hospital, CH-8091 Zurich, Switzerland. Tel: +41-44-634-2871; Fax: +41-44-634-2872;
E-mail: rolf.stahel@usz.ch
Both authors contributed equally to this manuscript.
ª 2007 European Society for Medical Oncology
The difficulty in providing adjuvant therapy after EPP led us
to carry out a pilot study at the University Hospital of Zu¨rich
with a neo-adjuvant approach using the best documented
combination chemotherapy at that time [14]. Nineteen patients
with potentially resectable mesothelioma were treated with
three cycles cisplatin and gemcitabine [15]. The response rate
was 32% and 16 patients underwent EPP with no perioperative
mortality and the median survival of all patients was 23
months. The aim of this trial SAKK 17/00 was to prospectively
evaluate neo-adjuvant chemotherapy followed by EPP
with or without radiotherapy in a multicenter setting in
Switzerland.
patients and methods
trial design
The original trial design was an optimal two-stage design for the primary
endpoint of operability after chemotherapy with the original target sample
size of 30 patients An operability rate of 50% or less is considered as
unworthy, while a rate of at least 80% is considered as promising for further
investigation. After confirming operability on 11 of 13 patients in stage I,
the sample size was increased to 61 patients to address questions
regarding the patients quality of life (QoL), with psychological distress as
the primary endpoint. The trial was approved by the appropriate local
ethics committees and Swissmedic.
eligibility criteria
Patients were eligible for the trial if they had a histologically confirmed
diagnosis of MPM, including all subtypes and clinical T1–T3, N0–2, M0
disease considered to be completely resectable as evaluated by a thoracic
oncology tumor board including a thoracic surgeon [16]. Mediastinoscopy
was carried out in all patients to exclude N3 disease. The choice to include
patients with N2 disease and sarcomatous histology was based on the
patient selection made in our pilot study [15]. Other requirements included
a World Health Organization performance status (PS) of zero to two,
a serum creatinine within normal limits, no major organ dysfunction,
no history of other malignancies, a calculated postoperative forced
expiratory volume in one second (FEV1) >40% of predicted value, and
a written informed consent. Patients were not eligible if they had had prior
pleurectomy or lung resection (except small biopsies for diagnostic
purposes) or contraindications to surgery or prior chemotherapy.
chemotherapy
Neo-adjuvant chemotherapy consisted of three cycles of cisplatin 80 mg/m2
on day 1 and gemcitabine 1000 mg/m2 on days 1, 8 and 15, given every
28 days. Dose modification was mandated as follows: Cisplatin was to be
reduced to 50% for a serum creatinine >120 lmol/l and omitted for
a serum creatinine >150 lmol/l. The dose of gemcitabine was to be reduced
to 75% for a neutrophil count <1.5 g/l or a platelet count <100 g/l and
omitted for a neutrophil count <1.0 g/l or a platelet count <75 g/l.
surgery
All patients were scheduled to undergo EPP. Reasons for inoperability
were a predicted postoperative FEV1 <40%, based on immediate
preoperative spirometry and lung perfusion scan or unresectability due
to tumor progression documented on chest computed tomography
scan after chemotherapy. The EPP was defined as an en bloc resection
of the entire pleura, lungs, ipsilateral diaphragm and pericardium as
described previously [15]. The ipsilateral peritracheal, infracarinal and
perioesophageal lymph nodes were resected. Additionally, the port
sites of the previous thoracoscopy and drain channels were resected.
Patients found to have a multilevel invasion of the chest wall or mediastinal
structures at thoracotomy were not resected.
The surgeons participating in this trial needed to have an experience
of at least 15 EPP carried out in the last 5 years.
radiotherapy
Radiotherapy was recommended to areas of obvious incomplete resection
and to high-risk areas as defined by the surgeon, such as the sinus
phrenicocostalis and sites of surgical incisions. Clips were to be placed at
areas of high risk and simulation of patients were to include consultation
with the thoracic surgeon and radiotherapy was limited to the clipped area
with a margin of 2–5 cm dependent on anatomical site and breath
dependent mobility. Radiation was to start within 8 weeks after surgery.
The radiotherapy dose recommended was 60 Gy in 2-Gy daily fraction
5 times per week for residual macroscopic disease and 50 Gy in 2-Gy daily
fraction 5 times per week for high-risk areas. If not radically resected,
port-site incisions were to be irradiated with a single dose of 1 · 8 Gy.
quality of life
QoL was assessed at registration, day 1 of cycle 3, and 1, 3 and 6 months
after surgery with the Rotterdam Symptom Checklist (RSCL) [17]. The
RSCL is a cancer-specific questionnaire consisting of subscales for physical
symptom distress, psychological distress, activity impairment and an
overall evaluation of QoL. Due to feasibility problems, the item decreased
sexual interest was replaced by chest pain (at the end of the symptom list)
and included in the physical symptom subscale. Change in weight was
added as single item in the same response format.
The amended sample size was calculated to assess changes from baseline
to 3 months after surgery, with the psychological distress scale (seven items)
as the primary endpoint. According to the recommendation of the RSCL
manual, a cut-off raw score of ‡15 was defined to detect probable cases of
psychological or psychiatric morbidity. To detect an improvement of
20% in the proportion of cases versus non cases with 90% power and
an a of 0.05 (one-sided), 53 patients were needed. Assuming missing data
in 15% of all patients a total sample of N = 61 was defined. If on a form
‡4 of these items were not answered, the distress score for this assessment
was considered as missing. If £3 items were not answered, the missing
values were replaced by the mean value of the answered items of this
assessment. The rate of patients below or above the cut-off was calculated
for the assessments at baseline and at 3 months after surgery and
compared with the one-sided exact McNemar’s test. The other items and
scales were analyzed descriptively. To facilitate comparison with other
studies, the raw scores of all items and scales were transformed to
a standardized scale with values from 0 (worst QoL condition) to 100
(best condition). For all items and scales, we considered a change of ‡8
points as clinically significant [18].
results
Sixty-one patients with MPM, 57 male and four female,
entered the trial from July 2000 to June 2003. The median age
was 59 years (range: 44–72). PS was zero in 37 patients, one
in 23 patients and two in one patient. Forty-two patients had
epithelial, 14 patients mixed and three patients sarcomatous
type of mesothelioma diagnosed at trial entry, while in two the
subtype of mesothelioma could not be ascertained. The
combination of clinical T and mediastinoscopically determined
N stage is given in Table 1.
Fifty-eight patients have completed the prescribed three
cycles of chemotherapy. Two patients went off-treatment after
one cycle because of progressive disease and one patient refused
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further treatment after two cycles. The incidence of grade 3 or
4 toxicity in 178 documented cycles were as follows: nausea and
vomiting 6%, other gastrointestinal toxic effects 1%, myalgia 2%
and dyspnea 1%, leucopenia 15% and thrombocytopenia 6%.
In all, 45 of 61 patients underwent EPP after neo-adjuvant
chemotherapy. The operability rate was thus 74%. All but
one of the operated patients underwent surgery within 6 weeks
of completion of the chemotherapy. In 37 patients, the tumor
was completely resectable as determined by the surgeon and
pathologist (R0 or R1) and in eight patients macroscopical
tumor was left behind (R2). The resectability rate was therefore
61%. The reasons for nonoperability in the 16 patients were as
follows: tumor progression or withdrawal of consent before
completion of neo-adjuvant chemotherapy (three patients),
tumor progression at time of completion of neo-adjuvant
chemotherapy (five patients), intraoperative decision because
of doubtful resectability (four patients), decrease in PS (two
patients) and tumor infiltration of the chest wall and
myocardial infarction (one patient each). After initial refusal
for surgery, one patient finally agreed to be operated 4 months
after chemotherapy and thus was considered in this analysis.
Major postoperative complications occurred in 16 (35%)
of the patients undergoing EPP. Mortality was 2.2% with one
in-hospital death in an obese patient with diabetes due to
respiratory infection and subsequent multi-organ failure. Other
major complications included respiratory infection (five
patients), chylothorax (two patients), bleeding, necessitating
reoperation (two patients), bronchial insufficiency (two
patients), as well as thrombosis, myocardial infarction,
pneumothorax and laryngeal nerve palsy (one patient each).
Supraventricular arrhythmias occurred in 11 patients.
The 45 operative specimens after EPP were examined for the
presence of necrosis. Tissue necrosis between 10 and 50% or
>50% was observed one in each specimen.
Radiotherapy after EPP was administered in 36 of 45
patients. Only in 24 patients radiotherapy was initiated within
the 8 weeks postoperatively, however. In six patients additional
protocol deviations were necessary because of deteriorating
condition or infection (four patients), tumor recurrence (one
patient) and radiation pneumonitis (one patient). There were
no grade 3–4 acute and long-term toxic effects.
With a median follow-up of 46 months the estimated median
survival for all 61 patients entering the trial was 19.8 months
[95% confidence interval (CI) 14.6–24.5] from the start of
chemotherapy (Figure 1A).
For the 45 patients undergoing EPP the estimated median
survival was 23 months (95% CI 16.6–32.9) (Figure 2A).
Tumor recurrence after EPP has been observed in 38 patients
with a median time to recurrence of 13.5 months (95% CI
10.2–18.8) (Figure 2B).
Operated patients with epithelial tumors tended to have
a better survival than patients with sarcomatoid and mixed
tumors with median survival of 21.9 months (95% CI 14.9–
29.3) versus 11.1 months (95% CI 9–19.8, log-rank P = 0.259)
(Figure 1B). When the European Organisation for Research
and Treatment of Cancer prognostic score [19] was applied
to our dataset, survival was 17.4 (range: 3.5–45.6+) months for
the high-risk group and 26.3 (range: 5.0–58.1+) months for
the low-risk group.
QoL data based on the RSCL was available in all but one
patient at baseline and from 93% (57 patients) at cycle 3.
Compliance after surgery remained high with RSCL available at
months 1, 3 and 6 after surgery in 86% (N = 38), 93% (N = 40)
and 94% (N = 36) of operated patients, respectively. In the
following section, varying numbers for a given QoL variable
and assessment time point are due to missing items on the
received forms. Overall, the operated cases showed a tendency
towards worse baseline scores than the nonoperated cases
(Table 2). Among the four global QoL domains, psychological
Table 1. Combinations of T and N stages (frequency of patients)
T stage N stage Total
0 1 2 ·
1 10 1 3 0 14
1a 1 0 0 0 1
1b 1 1 0 0 2
2 26 5 2 1 34
3 7 1 2 0 10
Total 45 8 7 1 61
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Figure 1. Survival time of all 61 patients by intent to treat analysis as
estimated by the Kaplan–Meier method (broken lines: 95% confidence
interval) (A) and survival according to histological type (epithelial: N = 38
versus sarcomatoid or mixed: N = 19) (B).
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distress was most impaired. It showed only minor variation
over time (Figure 3A). The rates of operated patients with
distress cut-off score indicating no morbidity showed
a nonsignificant decline from 82% (36 of 44 patients with
a QoL form) at baseline to 76% (26 of 34) at 3 months after
surgery (McNemar’s exact test for the 34 patients with both
QoL forms: P = 0.4). Six patients with a baseline score above
the cut-off indicated distress below the cut-off at 3 months after
surgery; four patients with baseline distress below the cut-off
indicated a score above the cut-off at 3 months after surgery.
Physical symptom distress showed the expected worsening at
1 (N = 34, median change = 216.7) and 3 months (N = 34,
median change = 211.6) after surgery, followed by a recovery
to a level close to baseline at 6 months after surgery (N = 30,
median change = 24.3). Activity level was high at baseline and
exhibited a similar pattern, with a considerable deterioration at
1 month after surgery (N = 33, median change = 254.2) and
recovery close to baseline at 6 months (N = 30, median
change = 24.5). Overall QoL was less impaired after surgery,
though it did not reach the baseline level 6 months thereafter
(N = 30, median change = 28.3) (Figures 3B, C and D).
Patients indicated tiredness, shortness of breath and chest
pain was likewise strong at baseline (Table 2). Chest pain
was worse at 1 month after surgery (N = 34, median
change = 216.7) and improved to baseline at 6 months after
surgery. Tiredness and shortness of breath showed the same
impairment at 1 and 3 months after surgery (both N = 34,
median changes = 233.3), followed by a recovery back to
baseline level. Patients perceived a change in weight at
3 months after surgery (N = 33, median change = 233.3),
followed by a recovery to baseline values (Figures 4A–D).
discussion
In our initial trial design, a rate of operability of 80% would
constitute a promising outcome warranting further exploration
of this approach. Based on an intention-to-treat analysis the
operability rate was 74%, and 64% of patients were judged to
be macroscopically completely resected by the surgeon. The
operatibilty and resectabilty rate might be partially dependent
on the effect of induction, chemotherapy the major
determination, however, is the stage of the disease at study
entry and the willingness of the surgeon to accept macroscopic
incompleteness after the EPP. These results, however, come
close to our high expectation set forth at the onset of the trial.
We are aware that the resectability rate might have been
influenced by several factors, including patient selection, the
effect of chemotherapy, the experience of the surgical team and
the willingness to accept a higher risk with the combined
modality approach.
In regard to survival, the results or this multicenter trial do
not substantially differ from those of our single-center pilot
study with—by intent to treat analysis—a median median
survival of 19.8 months (95% CI 14.6–24.5) and a median
survival of 23 months (95% CI 16.6–32.9). They compare
favorably with the results of the trimodality approach with
adjuvant chemotherapy of the group at Brigham’s Hospital [9].
While the published results so far are indicative that radical
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Figure 2. Survival (A) and time to recurrence (B) of the 45 patients
undergoing extrapleural peumonectomy (broken lines: 95% confidence
interval).
Table 2. Baseline quality-of-life scores
Operated patients Nonoperated patients
N Mediana
(25%–75%
quartile range)
N Mediana
(25%–75%
quartile range)
Dimension scores
Psychological
distress
44 77.8 (66.7–85.7) 13 81.0 (71.4–98.2)
Physical symptom
distress
44 89.9 (84.8–92.8) 13 92.4 (89.9–95.7)
Activities of daily
living
44 100.0 (87.5–100.0) 13 100.0 (95.8–100.0)
Overall quality
of life
44 83.3 (66.7–83.3) 12 83.3 (83.3–83.3)
Symptom scores
Tiredness 44 66.7 (66.7–100.0) 13 66.7 (66.7–100)
Shortness of breath 44 66.7 (66.7–100.0) 13 100.0 (66.7–100.0)
Change in weight 43 100.0 (66.7–100.0) 13 100.0 (66.7–100.0)
Chest pain 44 66.7 (66.7–100.0) 13 100.0 (66.7–100.0)
aScores range from 0 to 100, with higher scores indicating a better
condition.
Annals of Oncology original article
Volume 18 | No. 7 | July 2007 doi:10.1093/annonc/mdm093 | 1199
surgery may indeed be associated with a longer survival as
compared with chemotherapy alone, final proof of this concept
will only come from a randomized trial.
The criteria for selecting patients for EPP remain a matter of
debate. Our trial did not exclude patients with unfavorable
characteristics such as N2 disease and sarcomatous histology
Figure 3. Qualitly-of-life analysis with changes in (A) psychological distress, (B) physical symptom distress, (C) activity level and (D) overall quality of
life from baseline (standardized scores; range: 0–100) after three cycles of chemotherapy and 4 weeks, 3 months and 6 months after surgery. Higher
change scores indicate an improvement (median changes: white bars).
Figure 4. Analysis of major symptoms with changes in (A) tiredness, (B) shortness of breath, (C) weight change and (D) chest pain from baseline
(standardized scores) after three cycles of chemotherapy and 4 weeks, 3 months and 6 months after surgery. Higher change scores indicate an improvement
(median changes: white bars).
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based on the fact that long-term survival—although at a lower
level—has also been reported in these circumstances by others
[9] and in our pilot study [15]. We also included patients
with radiological T3 disease, if the extent of chest wall invasion
was such that the thoracic surgeon deemed a resection
possible. Based on cancer registry data, the incidence of newly
diagnosed patients with MPM in Switzerland during the years
of the trial was 137 cases per year [20]. Considering that
peak age-specific incidence is >70 years, we estimate that at
least 15% of patients <70 years with newly diagnosed MPM
took part of this trial.
The response rate of MPM to cisplatin and gemcitabine has
been reported to range between 16 and 47% [14, 21, 22] and
was 32% in our previous neo-adjuvant trial [15]. Because of the
inherent difficulties to assess responses, we, however, elected
not to determine radiological response in our trial. The
response to cisplatin and pemetrexed has been reported to
be 41% in advanced MPM [6] and most groups are now
exploring this combination in a neo-adjuvant approach.
Our perioperative or in-hospital mortality was 2.2% which
compares favorably with other reports of EPP without neo-
adjuvant chemotherapy [11–13]. Resection after chemotherapy
is technically more demanding due to a scarring reaction at the
dissection plane and patients are more susceptible to general
complications such as infections, acute respiratory distress
syndrome and others [23]. We observed as major surgical
complications arrhythmias in 35% followed by respiratory tract
infections in 10% and bleeding, chylothorax and bronchial
stump insufficiency in 4% each. All could be treated
successfully. Thus, while EPP after chemotherapy is
a demanding procedure, it can be carried out with an
acceptable mortality and morbidity, but should be reserved for
dedicated centers.
Within the observation period, tumor recurrence after EPP
has occurred in 84% of patients with a median time to
recurrence of 13.5 months. Radiotherapy can be effective for
local palliation and has been indicated to be of benefit for the
prevention of malignant seeding after invasive diagnostic
procedures [24, 25], however, this recently come in doubts by
another report [26]. Relapse in the ipsilateral hemithorax after
EPP has remained a major problem, despite the fact that
adjuvant radiotherapy has been part of trimodality therapy since
its inception [27]. A phase II trial from the Memorial Sloan-
Kettering Cancer Center of postoperative radiotherapy in high
doses indicated a decrease in the local failure rate to 6% without
apparent impact on survival [28]. Intensity-modulated
radiotherapy after EPP has been intensively investigated by the
M.D. Anderson group [29, 30] and appears also promising in
reducing the rate of local relapse. Whether high doses of
intensity-modulated or conformal radiotherapy are feasible and
provide better local control after EPP in a neo-adjuvant setting is
uncertain [31] and currently under investigation by our group.
In previous MPM trials, QoL endpoints were related to
chemotherapy effects [4, 6, 7, 32, 33]. We investigated QoL
across the whole trimodality treatment and hypothesized an
improvement of psychological distress at 3 months after
surgery. Psychological distress was most impaired among the
four global QoL dimensions. It showed only minor variation
over time despite the aggressiveness of the therapeutic
approach and a full recovery after a period of 6 months
which was longer than expected. Roughly every fourth to fifth
patient indicated psychological morbidity, pointing towards
the importance of supportive care interventions. Physical
symptoms and activity showed the expected worsening after
surgery, followed by a recovery back to baseline level.
While combination chemotherapy with a platin compound
and a folate antagonist is the recommended treatment of
patients with advanced disease, our results indicate that
patients with potentially operable MPM can be offered the
benefit of a more radical multimodality approach including
neo-adjuvant chemotherapy and EPP without major long-term
impairment on their QoL, if the treatment is carried out by an
experienced team.
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